Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy?
Although at week 8, the predictive capability of CAP/CTM v1.0 was 78.5%, ART was found to be a more accurate predictor of future SVR status with a rate of 92.9%.Conclusion: These results indicate that the presence or absence of serum HCV RNA, evaluated using ART at week 8 after the initiation of therapy, may be useful for predicting therapeutic outcomes in patients receiving triple therapy
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Background/Aims: We compared the predictive abilities of the Abbott Real Time hepatitis C virus (HCV) assay (ART) with those of standard serum HCV ribonucleic acid (RNA) detection methods in patients undergoing triple therapy, which involves treatment with a protease inhibitor combined with pegylated interferon and ribavirin.Materials and Methods: In this study, 28 patients underwent triple therapy.
📊
Key Findings & Data:The hepatitis C virus ribonucleic acid (HCV RNA) level of each patient was measured at weeks 0, 4, 8, and 12 after the initiation of therapy using the Roche COBAS AmpliPrep/COBAS TaqMan HCV assay version 1.0 (CAP/CTM v1.0) and ART.
💡
Conclusion & Impact:Although at week 8, the predictive capability of CAP/CTM v1.0 was 78.5%, ART was found to be a more accurate predictor of future SVR status with a rate of 92.9%.Conclusion: These results indicate that the presence or absence of serum HCV RNA, evaluated using ART at week 8 after the initiation of therapy, may be useful for predicting therapeutic outcomes in patients receiving triple therapy
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Background/Aims: We compared the predictive abilities of the Abbott Real Time hepatitis C virus (HCV) assay (ART) with those of standard serum HCV ribonucleic acid (RNA) detection methods in patients undergoing triple therapy, which involves treatment with a protease inhibitor combined with pegylated interferon and ribavirin.Materials and Methods: In this study, 28 patients underwent triple therapy. The hepatitis C virus ribonucleic acid (HCV RNA) level of each patient was measured at weeks 0, 4, 8, and 12 after the initiation of therapy using the Roche COBAS AmpliPrep/COBAS TaqMan HCV assay version 1.0 (CAP/CTM v1.0) and ART. Results: At week 8 after the initiation of therapy, the sustained virological response (SVR) rate among patients who tested negative and positive for HCV RNA using CAP/CTM v1.0, was 80.0% (20/25) and 33.3% (1/3), and using ART, it was 91.3% (21/23) and 0.0% (0/5), respectively. Although at week 8, the predictive capability of CAP/CTM v1.0 was 78.5%, ART was found to be a more accurate predictor of future SVR status with a rate of 92.9%.Conclusion: These results indicate that the presence or absence of serum HCV RNA, evaluated using ART at week 8 after the initiation of therapy, may be useful for predicting therapeutic outcomes in patients receiving triple therapy
🔖
Cite This Article
IKEDA, H., OKUSE, C., WATANABE, T., MATSUMOTO, N., MATSUNAGA, K., SHİGEFUKU, R., HATTORİ, N., HİRAİSHİ, T., FUKUDA, Y., NOGUCHİ, Y., ISHİİ, T., SHİMA, J., NAKAHARA, K., YAMAMOTO, H., YASUDA, H., YOTSUYANAGİ, H., KOİKE, K., ITOH, F., SUZUKİ, M. (2016). Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy?. Turkish Journal of Gastroenterology, Cilt: 27 - Sayı: 2, 165–172. https://ajindex.com/articles/411311
Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfu- sion-associated hepatitis C. N Engl J Med 1995
[CrossRef] Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999
[CrossRef] Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lan- cet 2001
[CrossRef] Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002
[CrossRef] McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with pe- ginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009
[CrossRef] Hezode C, Forestier N, Dusheiko G,, et al. Telaprevir and peginter- feron with or without ribavirin for chronic HCV infection. N Engl J Med 2009
[CrossRef] McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010
[CrossRef] Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011
[CrossRef] Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011
[CrossRef] Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011
[CrossRef] Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavi- rin therapy. Nat Genet 2009
[CrossRef] Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin ther- apy for chronic hepatitis C. Nat Genet 2009
[CrossRef] Al Olaby RR, Azzazy HM. Hepatitis C virus RNA assays: current and emerging technologies and their clinical applications. Expert Rev Mol Diagn 2011
[CrossRef] Chevaliez S. Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect 2011
[CrossRef] Strassl R, Rutter K, Stattermayer AF, et al. Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Disc